Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure Although digoxin has been widely used to treat patients with heart failure, its use has been surrounded by considerable controversy. The first controversy was whether its symptomatic benefits were only observable in patients with concomitant atrial fibrillation or whether patients in sinus rhythm and heart failure would also benefit. This issue was addressed in two well designed randomized trials, the RADIANCE study' 11 in patients on an angiotensin converting enzyme (ACE) inhibitor; and the PROVED study' 21 in those not receiving an ACE inhibitor. (See Appendix A on page 1688 for the full trial names) In both studies, patients with a low ejection fraction who were on digoxin were withdrawn and received a placebo or continued digoxin for 12 weeks. Patients who were randomized to continue digoxin demonstrated better exercise tolerance and less symptomatic deterioration in heart failure. However, these studies were too short and too small to assess the impact of digoxin on mortality or hospitalizations for heart failure. Furthermore, the withdrawal design and the inclusion of patients with low ejection fraction limited the generalizability of the results to a broader population.
A second controversy that has surrounded the use of digoxin was its impact on mortality'
31
. Several analyses of databases of patients with coronary artery disease suggested that patients using digoxin had a higher mortality compared to those not taking digoxin. Such studies cannot reliably distinguish whether the higher mortality was due to the drug or because sicker patients were prescribed the agent. In order to resolve this, the U.S. National Heart Lung and Blood Institute, the U.S. Veterans Affairs Department and investigators from over 300 hospitals in the U.S.A. and Canada collaborated in the Digitalis Investigation Group (DIG) trial, the largest clinical trial of heart failure, with 7788 patients' 41 . This study has several unusual features. First, it included patients irrespective of ejection fraction (2035 had ejection fraction over 0-35 and 988 over 0-45). Patients were recruited mainly from community hospitals so that the results have considerable generalizability. Treatment was prolonged with a mean duration of 37 months (range of 24 to 60 months), so that the true long-term effects of treatment could be assessed.
Over the entire course of the study there was a neutral impact on mortality with a 33-3% death rate in those allocated digoxin compared to 33-6% in the control group; (but an apparent beneficial effect over the first 12 months; death rates of 10-1% vs 11-5%, respectively; risk ratio of 0-87; /><0032), which contrasts with the concerns that led to the establishment of the trial. This overall neutral effect also contrasts with the consistent adverse effect on mortality seen with a number of other inotropic agents such as the phosphodiesterase inhibitors or ^-receptor antagonists' 5 ' 61 . There was a significant and substantial •(•Unpublished meta-analysis by Avezum A, Tsuyuki R and Yusuf S. *Data on mortality are available from about 85% of the patients randomized, and on heart failure hospitalizations from only 55% of the patients randomized. The relative risk reductions (especially on heart failure hospitalizations) are therefore unreliable and it is possible that the available data are inflated by selective publication of positive results. |Death/hospitalizations for chronic heart failure. EF = ejection fraction.
reduction in hospitalizations which was entirely due to the reduction in hospitalizations for heart failure (25-7% of patients in the digoxin group vs 33-1% in the control group, relative risk reduction of 27%, P<00001). There was a reduction in the number of multiple hospitalizations, so that the number of hospitalizations avoided was substantial and treatment of 1000 patients for one year avoided 53 hospital admissions*. The rates of serious digoxin toxicity were low. How do these effects of digoxin compare with the use of other treatments? In trials with patients with ejection fraction <0-35, long-term (mean of 41-4 months) ACE inhibitors reduced mortality by 16% and reduced the rates of death or hospitalizations by 26% [8] . Little data exist regarding the use of ACE inhibitors in individuals with more preserved ejection fraction. Note that it is only with digoxin that we have adequate long-term data in patients with ejection fraction >0-35, whereas the effects of other agents have not been systematically evaluated in such patients.
It is also worth noting that short-term trials may overestimate the treatment benefit of an agent. In the SOLVD Treatment Trial [8] , the relative risk reductions in mortality at 3 months was 33% (95% confidence index of 2 to 53%); at 1 year, the relative risk reductions had decreased to 23% and by 48 months to 17%. It is curious to note that there was a 'significant' difference in mortality at 1 year in the DIG trial in favour of digoxin (10-1% deaths in the digoxin group compared to 11-5% in the placebo group; a relative risk ratio of 13%, 'nominal' P=0032) which disappeared by the end of the trial. The impact of digoxin on hospitalizations for heart failure was larger at 3 months (relative risk ratio of 55%, / > <0001) than at the end of the trial (relative risk ratio of 27%, P<0001). The above considerations suggest that short-term trials of most agents in heart failure may be overtly optimistic (especially when the effect size is described in terms of the relative risk ratio) and that when comparing the results of different trials, great caution should be used to ensure that the results in individuals with similar characteristics and over a similar duration are being compared. Small studies of short duration may claim implausibly large effects on mortality and the observed effect size may not be reliable even when apparently highly statistically significant. Sometimes even the apparent direction of effect is misleading (type I error). A good example is the contrasting results between the initial experience with vesnarinone' 91 compared to the larger study'
101
. In an initial study of 259 patients'
81
, followed for only 6 months, use of vesnarinone for 6 months was associated with a highly significant and implausibly large (about a 50% relative risk ratio) reduction in mortality. A subsequent much larger trial of about 4000 patients' 101 demonstrated the opposite: a 27% increase in mortality with the same regimen of vesnarinone (/ ) <001)' 101 . Similar caution should be used in interpretation of the recent trials of betablockers. Data on short-term mortality with carvedilol were combined from several small shortterm trials'" 1 and probably published because they appeared promising and 'large'. A moderate-sized larger and longer term study suggested a more plausible and more modest reduction in mortality that was not statistically significant' 12 '. While the weight of the evidence regarding the effects of beta-blockers is favourable (unpublished metaanalysis by Avezum and Yusuf), the long-term effects of these agents will only be known after the completion of several well designed long-term trials that are underway. These examples serve to illustrate that apparently large effect sizes observed in small trials should not engender undue optimism and that large and longer term trials such as the DIG, SOLVD, VEST, PROMISE, PROFILE, etc. are needed to provide reliable estimates of treatment efficacy' 131 .
In summary, what have we learnt about digoxin from the recently conducted DIG trial? First, digoxin is the only oral positive inotropic agent which has made a clear and substantial reduction in hospitalizations, without an adverse impact on mortality. Second, these benefits are seen across a broad range of patients, including those with an ejection fraction >0-35 and those who were not previously on digoxin. Third, these benefits were observed on top of ACE inhibitors. Fourth, the effects were sustained over 4 years. Therefore, the DIG trial provides reliable evidence of the long-term benefits and safety of digoxin. This information will allow physicians to make appropriate judgements about the use of digoxin.
My approach would be initially to use ACE inhibitors in all patients with a low ejection fraction and heart failure in addition to diuretics (to relieve congestion). In high risk patients with heart failure who are likely to deteriorate (e.g. low ejection fraction, advanced NYHA class, enlarged heart), I
would additionally use digoxin to prevent worsening heart failure and to avoid hospitalizations. In the remaining patients, I would add digoxin when they demonstrate worsening symptoms or deterioration of left ventricular function, enlargement of their hearts or development of atrial fibrillation. Given the low cost, safety and clear benefit on morbidity, digoxin remains a useful drug in the management of heart failure.
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